Pharma badly prepared for incoming EU data regulation changes

10 July 2015
data-big

The pharma sector is poorly prepared for the major changes in data protection that the EU General Data Protection Regulation will bring, according to a survey by Crown Records Management.

One third of pharma companies are unaware of the forthcoming changes, predicted to be ratified in the next 12 months and in place in 2017. Crown Records Management commissioned a Censuswide Survey of IT decision-makers at UK companies employing more than 200 people to establish how well prepared businesses are for the changes.

Of these IT decision-makers in pharma, 28% were totally unaware of the changes, with only the insurance sector coming out worse. Almost a third said they were waiting for the final details of the regulation before taking any action, and one in three said their company is looking at staff training to prepare for the new regulation, which was the lowest across all sectors. Only 6% said they were planning to make no changes at all.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight